Menu
Annual · values202520242023202220212020201920182017201620152014
Gross Margin74.33%71.94%44.38%57.26%52.67%79.63%63.48%59.35%78.63%76.67%
Operating Margin
EBITDA Margin
Net Margin12.42%12.62%3.62%31.27%27.04%23.09%31.45%20.79%40.55%13.66%14.25%18.42%
Current Ratio1.161.170.911.221.401.350.881.571.351.251.492.67
Quick Ratio0.870.920.691.001.191.040.661.331.101.031.232.41
Debt / Equity0.750.730.810.370.500.630.820.650.610.700.600.51
ROE8.96%9.07%2.37%32.71%28.37%15.15%25.65%17.49%29.74%12.06%10.71%12.75%
ROA3.73%3.76%0.94%15.91%12.11%6.23%9.72%7.00%12.40%4.20%4.16%5.40%
Asset Turnover0.300.300.260.510.450.270.310.340.310.310.290.29
Book Value / Share15.1915.5315.6416.7313.5711.2710.6110.1211.229.229.8610.58

Pfizer Inc. is a leading biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells prescription drugs and vaccines worldwide. Operating in segments including Biopharma, PC1, and Pfizer Ignite, it focuses on key therapeutic areas such as oncology, cardiology, immunology, and infectious diseases. Notable products in its portfolio include the pneumococcal vaccine Prevnar 13, cardiovascular treatments like Vyndaqel and Eliquis, and oncology drug Padcev. Pfizer Inc. serves markets in the United States and internationally, with significant contributions from emerging markets representing a substantial portion of international sales. The company addresses critical health needs through innovative medicines that treat chronic and acute conditions, playing a vital role in global healthcare delivery. Founded in 1849 and headquartered in New York, New York, Pfizer Inc. maintains a broad presence in the pharmaceutical industry, supporting patients, healthcare providers, and public health initiatives across diverse regions.